Preliminary Injunction Granted Due to Weakened Invalidity Defense in Light of Inter Partes Review Decision

Sep 20, 2016

Reading Time : 1 min

The court considered four factors to determine whether the “drastic and extraordinary remedy” of a preliminary injunction was warranted. Beginning with the likelihood of success on the merits, the court only had to consider invalidity defenses. The defendants raised the obviousness ground that the PTAB had—for reasons of redundancy—declined to institute. The plaintiff’s challenges to the availability of this obviousness defense were unpersuasive to the court. Under recent Federal Circuit precedent, the defendants were not statutorily barred by estoppel under 35 U.S.C. § 315(e). Furthermore, the defendants were not precluded by common law issue preclusion. However, the court still found that the defendants were unlikely to prevail on the obviousness defense. The court also found that the defendants’ enablement defense was unlikely to prevail.

For the irreparable harm factor, the court found that the plaintiff had shown a real risk of being harmed by the defendants’ infringing technology if they were allowed to “capture and define” the developing and critically poised market for the technology at issue. The court then found that the balance of hardships factor weighed in favor of an injunction, and defendants’ alleged lost opportunities were the “price” of their conduct.

Finally, the court found that the public interest would be disserved without an injunction because laboratories, which grew to rely on potentially infringing technology, could end up facing liability of infringement.

Illumina, Inc. v. Qiagen, N.V., No. C 16-02788 WHA, 2016 WL 4719269 (N.D. Cal. Sept. 9, 2016) (Alsup, J.).

Share This Insight

Previous Entries

IP Newsflash

February 20, 2026

The Federal Circuit recently addressed whether the PTO must conduct notice‑and‑comment rulemaking before issuing instructions that guide how the Board should exercise discretion at the institution stage of IPRs. The court held that no such rulemaking is required. Instructions to the Board regarding its use of the Director’s delegated discretionary authority not to institute review are merely general statements of policy exempt from notice-and-comment rulemaking.  

...

Read More

IP Newsflash

February 18, 2026

The District Court for the District of Delaware recently invalidated claims directed to a panoramic objective lens for lack of enablement, holding the claims impermissibly recited a single element in means‑plus‑function form. Under § 112, ¶ 6, “[a]n element in a claim for a combination may be expressed as a means or step for performing a specified function….” By its plain terms, the statute permits means‑plus‑function claiming only in the context of a “combination.” In other words, a claim may not consist solely of a single means‑plus‑function element. Claims drafted as a single means are invalid for lack of enablement as a matter of law.

...

Read More

IP Newsflash

February 13, 2026

In an ANDA litigation, the District of Delaware recently denied the defendants’ motion to compel the production of correspondence between the plaintiffs’ testifying expert and a third-party analyst who had performed experiments and provided data used by the testifying expert. The court found that the scope of material sought by the motion was overbroad and disproportionate to the needs of the case.

...

Read More

IP Newsflash

February 12, 2026

In an ANDA litigation, the District of Delaware recently denied the plaintiffs’ motion to strike portions of the defendants’ expert reports and related deposition testimony. Although the defendants’ invalidity contentions did not state the specific theories of invalidity upon which the expert opined, the court found that none of the Pennypack factors supported excluding that expert testimony.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.